Excision BioTherapeutics Presents Positive Interim Clinical Data from Ongoing Phase 1/2 Trial of EBT
SAN FRANCISCO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies to cure viral infectious diseases, todayannounced positive safety data from the first dose cohort in its first-in-human Phase 1/2 trial to assess safety and pharmacodynamics of EBT-101. EBT-101 is a dual-guide, CRISPR-based investigational gene therapy for the